

Juan J GÃ³mez-Reino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/109904/publications.pdf>

Version: 2024-02-01

237
papers

29,652
citations

7096

78
h-index

4991

167
g-index

243
all docs

243
docs citations

243
times ranked

23618
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.9	3,366
2	Treating rheumatoid arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 631-637.	0.9	1,711
3	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 964-975.	0.9	1,429
4	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 3-15.	0.9	1,114
5	Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active surveillance report. <i>Arthritis and Rheumatism</i> , 2003, 48, 2122-2127.	6.7	889
6	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011, 63, 573-586.	6.7	864
7	Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis. <i>Science Translational Medicine</i> , 2010, 2, 52ra72.	12.4	774
8	Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. <i>Arthritis and Rheumatism</i> , 2008, 58, 2968-2980.	6.7	752
9	Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 88-96.	0.9	687
10	American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 404-413.	0.9	657
11	Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. <i>Arthritis and Rheumatism</i> , 2005, 52, 1766-1772.	6.7	612
12	Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2009, 60, 976-986.	6.7	547
13	Adipokines as emerging mediators of immune response and inflammation. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 716-724.	3.2	457
14	The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. <i>European Respiratory Journal</i> , 2010, 36, 1185-1206.	6.7	444
15	Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1198-1201.	0.9	437
16	Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. <i>Arthritis and Rheumatism</i> , 2007, 57, 756-761.	6.7	378
17	Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1020-1026.	0.9	372
18	Leptin in the interplay of inflammation, metabolism and immune system disorders. <i>Nature Reviews Rheumatology</i> , 2017, 13, 100-109.	8.0	371

#	ARTICLE	IF	CITATIONS
19	Leptin, from fat to inflammation: old questions and new insights. FEBS Letters, 2005, 579, 295-301.	2.8	337
20	The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine and Growth Factor Reviews, 2007, 18, 313-325.	7.2	316
21	Clinical efficacy and safety of abatacept in methotrexate-naïve patients with early rheumatoid arthritis and poor prognostic factors. Annals of the Rheumatic Diseases, 2009, 68, 1870-1877.	0.9	301
22	A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis and Rheumatism, 2012, 64, 970-981.	6.7	293
23	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Annals of the Rheumatic Diseases, 2016, 75, 16-22.	0.9	275
24	What's new in our understanding of the role of adipokines in rheumatic diseases?. Nature Reviews Rheumatology, 2011, 7, 528-536.	8.0	254
25	Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Research and Therapy, 2006, 8, R29.	3.5	250
26	A new player in cartilage homeostasis: adiponectin induces nitric oxide synthase type II and pro-inflammatory cytokines in chondrocytes. Osteoarthritis and Cartilage, 2008, 16, 1101-1109.	1.3	241
27	All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Annals of the Rheumatic Diseases, 2007, 66, 880-885.	0.9	196
28	Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-blind, Placebo-controlled Trials. Arthritis and Rheumatology, 2017, 69, 362-375.	5.6	189
29	Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Annals of the Rheumatic Diseases, 2011, 70, 1575-1580.	0.9	188
30	The potential of lipocalin-2/NGAL as biomarker for inflammatory and metabolic diseases. Biomarkers, 2015, 20, 565-571.	1.9	188
31	Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1133-1138.	0.9	186
32	Large-scale analysis of association between <i>GDF5</i> and <i>FRZB</i> variants and osteoarthritis of the hip, knee, and hand. Arthritis and Rheumatism, 2009, 60, 1710-1721.	6.7	181
33	Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Research and Therapy, 2015, 17, 362.	3.5	181
34	An SNP in the 5'-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage. Human Molecular Genetics, 2007, 16, 2226-2232.	2.9	180
35	Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial. American Journal of Ophthalmology, 2018, 195, 181-190.	3.3	177
36	Adipokines as novel modulators of lipid metabolism. Trends in Biochemical Sciences, 2009, 34, 500-510.	7.5	173

#	ARTICLE	IF	CITATIONS
37	Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2012, 64, 2504-2517.	6.7	171
38	Leptin beyond body weight regulation—Current concepts concerning its role in immune function and inflammation. <i>Cellular Immunology</i> , 2008, 252, 139-145.	3.0	168
39	Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. <i>Arthritis Research and Therapy</i> , 2006, 8, R72.	3.5	167
40	The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 687-695.	0.9	166
41	Adipokines: Biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity. <i>BioFactors</i> , 2011, 37, 413-420.	5.4	162
42	Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet</i> , The, 2018, 391, 2213-2224.	13.7	159
43	Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1010-1014.	0.9	149
44	Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1830-1835.	0.9	143
45	Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 2924-2937.	5.6	143
46	Synergistic induction of nitric oxide synthase type II: In vitro effect of leptin and interferon- γ in human chondrocytes and ATDC5 chondrogenic cells. <i>Arthritis and Rheumatism</i> , 2003, 48, 404-409.	6.7	136
47	Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. <i>Arthritis and Rheumatism</i> , 1999, 42, 989-992.	6.7	133
48	Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. <i>Rheumatology</i> , 2014, 53, 1872-1885.	1.9	132
49	Replication of recently identified systemic lupus erythematosus genetic associations: a case-control study. <i>Arthritis Research and Therapy</i> , 2009, 11, R69.	3.5	131
50	Adipokines, Metabolic Syndrome and Rheumatic Diseases. <i>Journal of Immunology Research</i> , 2014, 2014, 1-14.	2.2	130
51	Ghrelin, a widespread hormone: insights into molecular and cellular regulation of its expression and mechanism of action. <i>FEBS Letters</i> , 2003, 552, 105-109.	2.8	129
52	Immunogenicity of Monoclonal Antibodies Against Tumor Necrosis Factor Used in Chronic Immune-Mediated Inflammatory Conditions. <i>JAMA Internal Medicine</i> , 2013, 173, 1416.	5.1	129
53	Patient Perceptions concerning Pain Management in the Treatment of Rheumatoid Arthritis. <i>Journal of International Medical Research</i> , 2010, 38, 1213-1224.	1.0	128
54	Efficacy and safety of the human anti-IL-1 β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study. <i>BMC Musculoskeletal Disorders</i> , 2011, 12, 153.	1.9	128

#	ARTICLE	IF	CITATIONS
55	Lipid Profile Changes in Patients With Chronic Inflammatory Arthritis Treated With Biologic Agents and Tofacitinib in Randomized Clinical Trials: A Systematic Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2015, 67, 117-127.	5.6	125
56	Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 479-488.	2.0	122
57	Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 864-867.	0.9	119
58	Assessment of global DNA methylation in peripheral blood cell subpopulations of early rheumatoid arthritis before and after methotrexate. <i>Arthritis Research and Therapy</i> , 2015, 17, 233.	3.5	119
59	A review of peripheral tuberculous arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 1988, 18, 142-149.	3.4	116
60	Expanding the adipokine network in cartilage: identification and regulation of novel factors in human and murine chondrocytes. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 551-559.	0.9	108
61	Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure. <i>Journal of Rheumatology</i> , 2013, 40, 768-780.	2.0	108
62	Assessment of Osteoarthritis Candidate Genes in a Meta-Analysis of Nine Genome-Wide Association Studies. <i>Arthritis and Rheumatology</i> , 2014, 66, 940-949.	5.6	108
63	Association of PDCD1 with susceptibility to systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 50, 2590-2597.	6.7	106
64	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 482-492.	0.9	102
65	Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1751-1755.	0.9	96
66	New Sequence Variants in HLA Class II/III Region Associated with Susceptibility to Knee Osteoarthritis Identified by Genome-Wide Association Study. <i>PLoS ONE</i> , 2010, 5, e9723.	2.5	96
67	Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. <i>Rheumatology</i> , 2016, 55, rev374.	1.9	95
68	Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. <i>Arthritis and Rheumatism</i> , 1994, 37, 1528-1533.	6.7	94
69	Cancer in Patients with Rheumatic Diseases Exposed to TNF Antagonists. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 71-80.	3.4	94
70	Nontropical pyomyositis in adults. <i>Seminars in Arthritis and Rheumatism</i> , 1994, 23, 396-405.	3.4	92
71	Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. <i>Arthritis and Rheumatism</i> , 1996, 39, 2028-2034.	6.7	89
72	Effect of oleocanthal and its derivatives on inflammatory response induced by lipopolysaccharide in a murine chondrocyte cell line. <i>Arthritis and Rheumatism</i> , 2010, 62, 1675-1682.	6.7	88

#	ARTICLE	IF	CITATIONS
73	Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. <i>RMD Open</i> , 2015, 1, e000017-e000017.	3.8	86
74	Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. <i>Rheumatology International</i> , 2007, 27, 793-806.	3.0	85
75	Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 1264-1274.	6.7	85
76	Adiponectin and Leptin Induce VCAM-1 Expression in Human and Murine Chondrocytes. <i>PLoS ONE</i> , 2012, 7, e52533.	2.5	84
77	Adipokines in the skeleton: influence on cartilage function and joint degenerative diseases. <i>Journal of Molecular Endocrinology</i> , 2009, 43, 11-18.	2.5	83
78	Leptin: A metabolic hormone that functions like a proinflammatory adipokine. <i>Drug News and Perspectives</i> , 2006, 19, 21.	1.5	83
79	Further evidence for the anti-inflammatory activity of oleocanthal: Inhibition of MIP-1 α and IL-6 in J774 macrophages and in ATDC5 chondrocytes. <i>Life Sciences</i> , 2012, 91, 1229-1235.	4.3	80
80	Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 583-589.	0.9	80
81	Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 9-17.	3.4	76
82	Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 149-156.	3.4	76
83	Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 690-698.	0.9	76
84	Adiponectin and leptin increase IL-8 production in human chondrocytes. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2052-2054.	0.9	75
85	Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1861-1864.	0.9	74
86	Reference genes for normalization of gene expression studies in human osteoarthritic articular cartilage. <i>BMC Molecular Biology</i> , 2008, 9, 17.	3.0	73
87	At the crossroad between immunity and metabolism: focus on leptin. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 801-808.	3.0	71
88	Sustained disease remission and inhibition of radiographic progression in methotrexate-naïve patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1949-1956.	0.9	71
89	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1999-2002.	0.9	71
90	Male lupus: Retrospective analysis of the clinical and laboratory features of 52 patients, with a review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 1989, 18, 189-197.	3.4	69

#	ARTICLE	IF	CITATIONS
91	Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 988-990.	0.9	66
92	Keratinocyte apoptosis and p53 expression in cutaneous lupus and dermatomyositis. , 1999, 188, 63-68.		64
93	Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 374-377.	0.9	64
94	High Sodium Intake Is Associated With Self-Reported Rheumatoid Arthritis. <i>Medicine (United States)</i> , 2015, 94, e0924.	1.0	64
95	Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 382-385.	0.9	61
96	Outcome of silent lupus nephritis. <i>Seminars in Arthritis and Rheumatism</i> , 1996, 26, 468-476.	3.4	60
97	Survival analysis of 306 European Spanish patients with systemic lupus erythematosus. <i>Lupus</i> , 1998, 7, 159-163.	1.6	60
98	Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 524-533.	3.4	60
99	Efficacy and Safety of TNF Antagonists in Sarcoidosis: Data from the Spanish Registry of Biologics BIOBADASER and a Systematic Review. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 89-103.	3.4	59
100	Differential expression of adipokines in infrapatellar fat pad (IPFP) and synovium of osteoarthritis patients and healthy individuals. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 631-633.	0.9	59
101	Lack of association of a variable number of aspartic acid residues in the asporin gene with osteoarthritis susceptibility: case-control studies in Spanish Caucasians. <i>Arthritis Research and Therapy</i> , 2006, 8, R55.	3.5	58
102	Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1536-1544.	0.9	58
103	CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2013-2016.	0.9	56
104	Beyond Fat Mass: Exploring the Role of Adipokines in Rheumatic Diseases. <i>Scientific World Journal</i> , The, 2011, 11, 1932-1947.	2.1	56
105	Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors. <i>Arthritis and Rheumatism</i> , 2009, 60, 2558-2564.	6.7	55
106	Role of Adipokines in Atherosclerosis: Interferences with Cardiovascular Complications in Rheumatic Diseases. <i>Mediators of Inflammation</i> , 2012, 2012, 1-14.	3.0	54
107	A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1598-1602.	0.9	54
108	Adipokines as drug targets in joint and bone disease. <i>Drug Discovery Today</i> , 2014, 19, 241-258.	6.4	53

#	ARTICLE	IF	CITATIONS
109	Cutaneous Adverse Events During Treatment of Chronic Inflammatory Rheumatic Conditions With Tumor Necrosis Factor Antagonists: Study Using the Spanish Registry of Adverse Events of Biological Therapies in Rheumatic Diseases. Arthritis Care and Research, 2013, 65, 2024-2031.	3.4	52
110	Analysis of TNFAIP3, a feedback inhibitor of nuclear factor- κ B and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility. Arthritis Research and Therapy, 2009, 11, R42.	3.5	51
111	Akt activity protects rheumatoid synovial fibroblasts from Fas-induced apoptosis by inhibition of Bid cleavage. Arthritis Research and Therapy, 2010, 12, R33.	3.5	51
112	Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. Annals of the Rheumatic Diseases, 2013, 72, 83-88.	0.9	51
113	Large replication study and meta-analyses of DVWA as an osteoarthritis susceptibility locus in European and Asian populations. Human Molecular Genetics, 2009, 18, 1518-1523.	2.9	50
114	Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review. Seminars in Arthritis and Rheumatism, 2011, 40, 330-337.	3.4	49
115	Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis. Annals of the Rheumatic Diseases, 2014, 73, 871-882.	0.9	49
116	Matrix metalloproteinase-8 deficiency increases joint inflammation and bone erosion in the K/BxN serum-transfer arthritis model. Arthritis Research and Therapy, 2010, 12, R224.	3.5	48
117	Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 298-305.	0.9	47
118	The risk of tuberculosis in patients treated with TNF antagonists. Expert Review of Clinical Immunology, 2011, 7, 329-340.	3.0	46
119	Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal) Tj ETQq1 1 0.784314 rgBT /Overl 2012, 77, 372-382.	2.4	45
120	An update on leptin as immunomodulator. Expert Review of Clinical Immunology, 2014, 10, 1165-1170.	3.0	45
121	Clonally expanded lymphocytes in the minor salivary glands of sjögren's syndrome patients without lymphoproliferative disease. Arthritis and Rheumatism, 1994, 37, 1441-1444.	6.7	44
122	Invasive aspergillosis in systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 1995, 24, 304-314.	3.4	44
123	Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry. Rheumatology, 2011, 50, 1999-2004.	1.9	44
124	Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naïve subjects with rheumatoid arthritis: the phase III FILM trial. Annals of the Rheumatic Diseases, 2012, 71, 1289-1296.	0.9	43
125	NUCB2/nesfatinin: A new adipokine expressed in human and murine chondrocytes with proinflammatory properties, an in vitro study. Journal of Orthopaedic Research, 2014, 32, 653-660.	2.3	43
126	SERPINE2 Inhibits IL-1 β -Induced MMP-13 Expression in Human Chondrocytes: Involvement of ERK/NF- κ B/AP-1 Pathways. PLoS ONE, 2015, 10, e0135979.	2.5	42

#	ARTICLE	IF	CITATIONS
127	A CTLA-4 polymorphism associated with susceptibility to systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 50, 328-329.	6.7	40
128	Expression and modulation of ghrelin <i>O</i>-acyltransferase in cultured chondrocytes. <i>Arthritis and Rheumatism</i> , 2009, 60, 1704-1709.	6.7	39
129	Maintenance of remission following 2-3 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 564-568.	0.9	39
130	Genetic variation including nonsynonymous polymorphisms of a major aggrecanase, ADAMTS-5, in susceptibility to osteoarthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 435-441.	6.7	38
131	Predictors of treatment failure and mortality in native septic arthritis. <i>Clinical Rheumatology</i> , 2015, 34, 1961-1967.	2.2	38
132	Specific premature epigenetic aging of cartilage in osteoarthritis. <i>Aging</i> , 2016, 8, 2222-2231.	3.1	38
133	Regulatory polymorphisms in extracellular matrix protease genes and susceptibility to rheumatoid arthritis: a case-control study. <i>Arthritis Research and Therapy</i> , 2006, 8, R1.	3.5	37
134	Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naïve patients with Early Erosive rheumatoid arthritis (AGREE). <i>Arthritis Research and Therapy</i> , 2015, 17, 157.	3.5	37
135	Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. <i>Arthritis Research and Therapy</i> , 2016, 18, 50.	3.5	37
136	Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study. <i>Arthritis Research and Therapy</i> , 2010, 12, R72.	3.5	36
137	Particular association of clinical and genetic features with autoimmunity to citrullinated Î±-enolase in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 654-661.	6.7	36
138	Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. <i>Rheumatology</i> , 2011, 50, 85-92.	1.9	36
139	Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review. <i>Rheumatology International</i> , 2016, 36, 1043-1063.	3.0	36
140	Abatacept for the treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 319-326.	3.0	34
141	Apoptosis and Proliferation of Fibroblasts During Postnatal Skin Development and Scleroderma in the Tight-skin Mouse. <i>Journal of Histochemistry and Cytochemistry</i> , 1997, 45, 711-719.	2.5	33
142	Novel DNASE I mutations related to systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 50, 4070-4071.	6.7	32
143	Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 238-245.	1.5	32
144	Anti-Carbamylated Protein Antibodies as a Reproducible Independent Type of Rheumatoid Arthritis Autoantibodies. <i>PLoS ONE</i> , 2016, 11, e0161141.	2.5	32

#	ARTICLE	IF	CITATIONS
145	Partial protection against collagen antibody-induced arthritis in PARP-1 deficient mice. <i>Arthritis Research and Therapy</i> , 2006, 8, R14.	3.5	31
146	A broad analysis of IL1 polymorphism and rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 1947-1957.	6.7	31
147	Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 3 studies. <i>RMD Open</i> , 2018, 4, e000669.	3.8	31
148	Maintenance therapy of lupus nephritis with mycophenolate or azathioprine: systematic review and meta-analysis. <i>Rheumatology</i> , 2014, 53, 834-838.	1.9	30
149	Adipokines induce pro-inflammatory factors in activated Cd4+ T cells from osteoarthritis patient. <i>Journal of Orthopaedic Research</i> , 2017, 35, 1299-1303.	2.3	30
150	Further Evidence of Subphenotype Association with Systemic Lupus Erythematosus Susceptibility Loci: A European Cases Only Study. <i>PLoS ONE</i> , 2012, 7, e45356.	2.5	28
151	Lysophosphatidic acid receptor 1 suppression sensitizes rheumatoid fibroblast-like synoviocytes to tumor necrosis factor-induced apoptosis. <i>Arthritis and Rheumatism</i> , 2012, 64, 2460-2470.	6.7	28
152	New drugs from ancient natural foods. Oleocanthal, the natural occurring spicy compound of olive oil: a brief history. <i>Drug Discovery Today</i> , 2015, 20, 406-410.	6.4	28
153	Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry. <i>Rheumatology International</i> , 2019, 39, 509-515.	3.0	28
154	Polymorphism of the interleukin-1 receptor antagonist gene: A factor in susceptibility to rheumatoid arthritis in a Spanish population. <i>Arthritis and Rheumatism</i> , 2005, 52, 3015-3019.	6.7	27
155	Biologic monotherapy as initial treatment in patients with early rheumatoid arthritis. <i>Rheumatology</i> , 2012, 51, v31-v37.	1.9	27
156	Five-year Efficacy and Safety of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Methotrexate- and Biologic-naïve or Free of Methotrexate for 6 Months: the AMBITION Study. <i>Journal of Rheumatology</i> , 2017, 44, 142-146.	2.0	27
157	Internuclear ophthalmoplegia in systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 1998, 28, 179-186.	3.4	26
158	DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists. <i>BMC Musculoskeletal Disorders</i> , 2009, 10, 91.	1.9	26
159	Nitric oxide boosts TLR4 mediated lipocalin 2 expression in chondrocytes. <i>Journal of Orthopaedic Research</i> , 2013, 31, 1046-1052.	2.3	25
160	Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis. <i>Arthritis Research and Therapy</i> , 2014, 16, R66.	3.5	25
161	Visfatin as a therapeutic target for rheumatoid arthritis. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 607-618.	3.4	25
162	Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. <i>RMD Open</i> , 2021, 7, e001486.	3.8	24

#	ARTICLE	IF	CITATIONS
163	Variants Within STAT Genes Reveal Association with Anticitrullinated Protein Antibody-negative Rheumatoid Arthritis in 2 European Populations. <i>Journal of Rheumatology</i> , 2012, 39, 1509-1516.	2.0	23
164	Non-HLA genes PTPN22, CDK6 and PADI4 are associated with specific autoantibodies in HLA-defined subgroups of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2014, 16, 414.	3.5	23
165	Both HLA class II and class III DNA polymorphisms are linked to juvenile rheumatoid arthritis susceptibility. <i>Clinical Immunology and Immunopathology</i> , 1990, 56, 22-28.	2.0	22
166	Rheumatoid factor and response to TNF antagonists in rheumatoid arthritis: Systematic review and meta-analysis of observational studies. <i>Joint Bone Spine</i> , 2014, 81, 41-50.	1.6	22
167	Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: Table 1. <i>Rheumatology</i> , 2016, 56, kew271.	1.9	22
168	Association of anti-citrullinated vimentin and anti-citrullinated ã-enolase antibodies with subsets of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 3102-3110.	6.7	21
169	FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors. <i>Pharmacogenomics</i> , 2015, 16, 333-345.	1.3	21
170	Anti-carbamylated protein autoantibodies associated with mortality in Spanish rheumatoid arthritis patients. <i>PLoS ONE</i> , 2017, 12, e0180144.	2.5	21
171	Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment. <i>RMD Open</i> , 2018, 4, e000615.	3.8	20
172	Observational study of optimization of biologic therapies in rheumatoid arthritis: a single-centre experience. <i>Rheumatology International</i> , 2014, 34, 1059-1063.	3.0	19
173	Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept. <i>PLoS ONE</i> , 2019, 14, e0213073.	2.5	19
174	Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study. <i>PLoS ONE</i> , 2016, 11, e0153140.	2.5	19
175	Differential contribution of C4 and HLA-DQ genes to systemic lupus erythematosus susceptibility. <i>Human Genetics</i> , 1993, 91, 579-584.	3.8	18
176	Ghrelin, the Same Peptide for Different Functions: Player or Bystander?. <i>Vitamins and Hormones</i> , 2005, 71, 405-432.	1.7	18
177	El uso de abatacept en artritis reumatoide: revisi3n de la evidencia y recomendaciones. <i>ReumatologÃa ClÃnica</i> , 2013, 9, 5-17.	0.5	18
178	Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. <i>Scientific Reports</i> , 2018, 8, 7342.	3.3	18
179	Worsening of obstructive sleep apnoeas in a patient with rheumatoid arthritis treated with anti-tumor necrosis factor. <i>Respiratory Medicine</i> , 2004, 98, 123-125.	2.9	17
180	Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration. <i>Journal of Rheumatology</i> , 2017, 44, 162-169.	2.0	17

#	ARTICLE	IF	CITATIONS
181	Pseudoaneurysm of the popliteal artery as a complication of an osteochondroma. <i>Skeletal Radiology</i> , 1979, 4, 26-28.	2.0	15
182	Lack of Association with Rheumatoid Arthritis of Selected Polymorphisms in 4 Candidate Genes: CFH, CD209, Eotaxin-3, and MHC2TA. <i>Journal of Rheumatology</i> , 2009, 36, 1590-1595.	2.0	15
183	Health-related quality of life in psoriatic arthritis patients in Spain. <i>ReumatologÃa ClÃnica</i> , 2014, 10, 25-31.	0.5	15
184	Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial. <i>Rheumatology</i> , 2021, 60, 256-262.	1.9	14
185	Association of Systemic Lupus Erythematosus Clinical Features with European Population Genetic Substructure. <i>PLoS ONE</i> , 2011, 6, e29033.	2.5	14
186	Study of DNASE I gene polymorphisms in systemic lupus erythematosus susceptibility. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 560-561.	0.9	13
187	Novel factors as therapeutic targets to treat diabetes. Focus on leptin and ghrelin. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 583-591.	3.4	13
188	Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis. <i>PLoS ONE</i> , 2018, 13, e0196793.	2.5	13
189	Specific Association of HLA â€œ DRB 1*03 With Antiâ€œCarbamylated Protein Antibodies in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 331-339.	5.6	13
190	Ultrasonographic Assessment of Enthesitis in HLA-B27 Positive Patients with Rheumatoid Arthritis, a Matched Case-Only Study. <i>PLoS ONE</i> , 2013, 8, e58616.	2.5	13
191	Cis-regulation of IRF5 expression is unable to fully account for systemic lupus erythematosus association: analysis of multiple experiments with lymphoblastoid cell lines. <i>Arthritis Research and Therapy</i> , 2011, 13, R80.	3.5	12
192	Longâ€œTerm Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials. <i>ACR Open Rheumatology</i> , 2020, 2, 459-470.	2.1	12
193	Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register. <i>Arthritis Research and Therapy</i> , 2020, 22, 143.	3.5	12
194	Bone metabolism and adipokines: are there perspectives for bone diseases drug discovery?. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 945-957.	5.0	11
195	Lack of replication of higher genetic risk load in men than in women with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2014, 16, R128.	3.5	11
196	Apremilast for the treatment of psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 1281-1290.	3.0	11
197	Abnormal carnitine distribution in the muscles of patients with idiopathic inflammatory myopathy. <i>Arthritis and Rheumatism</i> , 1996, 39, 1869-1874.	6.7	10
198	Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis. <i>Current Therapeutic Research</i> , 2020, 93, 100601.	1.2	10

#	ARTICLE	IF	CITATIONS
199	Unlike ghrelin, obestatin does not exert any relevant activity in chondrocytes. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1399-1400.	0.9	9
200	Poly(ADP-ribose) polymerase suppression protects rheumatoid synovial fibroblasts from Fas-induced apoptosis. <i>Rheumatology</i> , 2008, 48, 483-489.	1.9	9
201	Rheumatoid arthritis response to treatment across IgG1 allotype “anti-TNF incompatibility: a case-only study. <i>Arthritis Research and Therapy</i> , 2015, 17, 63.	3.5	9
202	An Eco RI polymorphic site in the human complement C4 gene distinguishes Juvenile Rheumatoid Arthritis (JRA) susceptibility-bearing haplotypes. <i>Molecular Immunology</i> , 1989, 26, 427-430.	2.2	8
203	Bias in effect size of systemic lupus erythematosus susceptibility loci across Europe: a case-control study. <i>Arthritis Research and Therapy</i> , 2012, 14, R94.	3.5	8
204	Genetic risk load and age at symptom onset of knee osteoarthritis. <i>Journal of Orthopaedic Research</i> , 2012, 30, 905-909.	2.3	8
205	Spanish transcultural adaptation and validation of the English version of the compliance questionnaire in rheumatology. <i>Rheumatology International</i> , 2018, 38, 467-472.	3.0	8
206	The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs. <i>Pharmacological Research</i> , 2019, 148, 104410.	7.1	8
207	Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry. <i>Clinical Rheumatology</i> , 2021, 40, 3979-3988.	2.2	8
208	Bf polymorphisms in systemic lupus erythematosus patients of Spanish descent. <i>Arthritis and Rheumatism</i> , 1986, 29, 932-933.	6.7	7
209	Ghrelin plasmatic levels in patients with fibromyalgia. <i>Rheumatology International</i> , 2005, 25, 6-8.	3.0	7
210	Impact of treatment with TNF antagonists on total cholesterol in patients with ankylosing spondylitis and psoriatic arthritis. <i>Clinical Rheumatology</i> , 2017, 36, 1167-1172.	2.2	7
211	Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies. <i>ACR Open Rheumatology</i> , 2020, 2, 543-554.	2.1	7
212	Infections in Patients with Rheumatic Diseases Treated with TNF Antagonists. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 1418-1425.	1.6	6
213	Association of a BMP5 microsatellite with knee osteoarthritis: case-control study. <i>Arthritis Research and Therapy</i> , 2012, 14, R257.	3.5	5
214	The JAK inhibitor tofacitinib for active rheumatoid arthritis: results from Phase III trials. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 315-326.	0.3	5
215	Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: case-control study. <i>Arthritis Research and Therapy</i> , 2014, 16, 436.	3.5	5
216	Effect of lysophosphatidic acid receptor inhibition on bone changes in ovariectomized mice. <i>Journal of Bone and Mineral Metabolism</i> , 2015, 33, 383-391.	2.7	5

#	ARTICLE	IF	CITATIONS
217	Chemical exposure-induced systemic fibrosing disorders: Novel insights into systemic sclerosis etiology and pathogenesis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1226-1237.	3.4	5
218	Predictors of Response to TNF Antagonists. <i>Current Pharmaceutical Design</i> , 2014, 21, 221-232.	1.9	5
219	Autoantibodies in Sera from Patients with L-Tryptophan-Associated Eosinophilia-Myalgia Syndrome. <i>Clinical Immunology and Immunopathology</i> , 1995, 76, 115-119.	2.0	4
220	Rheumatoid factor does not predict response to TNF antagonists in rheumatoid arthritis: Three centers experience. <i>Joint Bone Spine</i> , 2013, 80, 438-440.	1.6	4
221	Factor B activation in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1990, 33, 1598-1599.	6.7	3
222	Eficacia y seguridad de golimumab aÃ±adido a fármacos antirreumáticos modificadores de la enfermedad en artritis reumatoide. Resultados del estudio GO-MORE en España. <i>Reumatología Clínica</i> , 2015, 11, 144-150.	0.5	3
223	Documento práctico para el uso de abatacept subcutáneo. <i>Reumatología Clínica</i> , 2014, 10, 218-226.	0.5	2
224	Efficacy and Safety of Golimumab as Add-on Therapy to Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Results of the GO-MORE Study in Spain. <i>Reumatología Clínica (English Edition)</i> , 2015, 11, 144-150.	0.3	2
225	The NICE position on indications for biologics and biosimilars. <i>Nature Reviews Rheumatology</i> , 2016, 12, 255-256.	8.0	2
226	Efficacy of different doses of rituximab for the treatment of RA: data From the CERERRA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A13.2-A14.	0.9	2
227	PULMONARY HYPERTENSION IN CONNECTIVE TISSUE DISEASES. <i>Rheumatology</i> , 1994, 33, 796-797.	1.9	1
228	Inflammation and HIV infection: a friendly connection. <i>Lancet, The</i> , 1996, 348, S24.	13.7	1
229	Reply. <i>Arthritis and Rheumatism</i> , 2013, 65, 542-542.	6.7	1
230	Le facteur rhumatoïde ne semble pas prédire la réponse aux anti-TNF Î± dans la polyarthrite rhumatoïde: expérience de trois centres. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2013, 80, 527-528.	0.0	1
231	Identification of three new cis-regulatory IRF5 polymorphisms: in vitro studies. <i>Arthritis Research and Therapy</i> , 2013, 15, R82.	3.5	1
232	Consensus on the use of Rituximab in Rheumatoid Arthritis. A document with evidence based recommendations. <i>Reumatología Clínica (English Edition)</i> , 2011, 7, 30-44.	0.3	0
233	Potential role of apremilast for the treatment of psoriatic arthritis. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 259-266.	0.3	0
234	166-Long-term (156-week) improvements in dactylitis and enthesitis with apremilast in psoriatic arthritis subjects: analysis of a large, pooled PALACE 1-3 database. <i>Rheumatology</i> , 2018, 57, .	1.9	0

#	ARTICLE	IF	CITATIONS
235	Ghrelin in the Local Regulation of Endocrine Glands. , 2006, , 869-875.		0
236	Adipokines, Molecular Players at the Crossroad Between Inflammation and Oxidative Stress: Role in Arthropathies. , 2013, , 67-88.		0
237	Risk/benefit management in the infectious phase in systemic autoimmune rheumatic diseases. Handbook of Systemic Autoimmune Diseases, 2020, , 179-203.	0.1	0